A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Trial Details

NCT ID

NCT06008054

Phase

PHASE2

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

• SI-B003
• BL-B01D1
• PD-1 Monoclonal Antibody

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Sign the informed consent form voluntarily and follow the protocol requirements;
• Gender is not limited;
• Age: ≥18 years old and ≤75 years old;
• Expected survival time ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.